Interim analysis of the German non-interventional post marketing surveillance study (NIS) on Quality of Life (QoL) of capecitabine in patients with metastatic breast cancer (MBC).

Zaiss, M., Fuxius, S., Lerchenmueller, C., Hahn, L., Luhn, B., Marschner, N., Steffens, C.C., Soeling, U., Mueller, V., 2010.

Ann Oncol 21 (suppl 8)(314P), viii108. doi:10.1093/annonc/mdq517

Abstract